Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1725 participants.
Also called NCT02680574
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,725 participants
- Sponsor
- Registry
-
NCT02680574 -
2015-004774-14
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Malaysia, Mexico, New Zealand, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02680574. Randomized; no masking; primary purpose treatment. Start 2016-02 (actual); primary completion 2020-06-18 (actual). Results posted on 2022-06-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Condition
- Anemia
- Condition
- Non-Dialysis-Dependent Chronic Kidney Disease
- Intervention (Drug)
- Vadadustat
- Intervention (Drug)
- Darbepoetin alfa
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct02680574- Content hash
573c8b141c26236f4c09371d7789924cf48e538258a2f3cf51ed21f084f449dc